| P2093 | author name string | Yueping Li | |
| | Qing Yang | |
| | Bin Hu | |
| | Zhijian Wang | |
| | Hanying Ma | |
| | Yujie Zhou | |
| | Qian Ma | |
| | Yingxin Zhao | |
| | Yuyang Liu | |
| | Dongmei Shi | |
| | Ruifang Liu | |
| | Bin Nie | |
| | Hongya Han | |
| | Shiwei Yang | |
| | Zhe Fang | |
| | Congya Bu | |
| P2860 | cites work | Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway | Q44307951 |
| | Relation of inflammation and benefit of statins after percutaneous coronary interventions | Q44382953 |
| | Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome | Q44916110 |
| | Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction | Q45098728 |
| | Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA). | Q45168727 |
| | Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial | Q45285899 |
| | Intensive lipid lowering with atorvastatin in patients with stable coronary disease | Q45310626 |
| | HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats | Q46384803 |
| | The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome | Q46427057 |
| | Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography | Q46567585 |
| | Troponin Elevation After Percutaneous Coronary Intervention Directly Represents the Extent of Irreversible Myocardial Injury | Q57744071 |
| | Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease | Q58375411 |
| | Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome | Q28240315 |
| | Selected major risk factors and global and regional burden of disease | Q29614888 |
| | Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 |
| | Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial | Q29622926 |
| | Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial | Q33940282 |
| | The global burden of chronic diseases: overcoming impediments to prevention and control | Q34323994 |
| | Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization | Q34448710 |
| | Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial | Q34561754 |
| | The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 |
| | Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome | Q36418965 |
| | Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study | Q36984049 |
| | Statin therapy in the elderly: a review | Q37393348 |
| | Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 |
| | A new paradigm for plaque stabilization | Q40641936 |
| | Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction | Q42868349 |
| | Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study | Q43207159 |
| | Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial | Q43607472 |
| | The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells | Q44134020 |
| P433 | issue | 7 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P304 | page(s) | 590-595 | |
| P577 | publication date | 2013-08-28 | |
| P1433 | published in | Angiology | Q4763277 |
| P1476 | title | Protective role of statins in patients with acute coronary syndrome aged ≥ 75 years with low LDL-C who underwent percutaneous coronary intervention | |
| P478 | volume | 65 | |